SCHEDULE 13G/A: Bain Capital Life Sciences Discloses 9.99% Stake in Olema Pharmaceuticals

Bain Capital Life Sciences Opportunities IV, L.P. has reported a 9.99% beneficial ownership stake in Olema Pharmaceuticals, Inc., totaling 6,843,954 shares, as detailed in its latest Schedule 13G filing.

Summary

• Bain Capital Life Sciences Opportunities IV, L.P. (the "Reporting Person") filed an Amendment No. 2 to Schedule 13G, disclosing its beneficial ownership in OLEMA PHARMACEUTICALS, INC.
• The Reporting Person beneficially owns 6,843,954 shares of Olema Pharmaceuticals' Common Stock.
• This ownership represents 9.99% of the total outstanding Common Stock of Olema Pharmaceuticals.
• The reported ownership includes 6,696,640 shares of Common Stock directly held and pre-funded warrants to purchase up to 8,013,216 additional shares of Common Stock.
• A "Beneficial Ownership Blocker" provision prevents the Reporting Person from exercising the pre-funded warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
• The percentage of ownership is calculated based on 68,360,752 shares of Common Stock outstanding as of April 21, 2025, as reported by the Issuer, plus 147,314 shares issuable upon partial exercise of the pre-funded warrants held by the Reporting Person.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, consistent with a passive investment.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive investment by a major life sciences fund, which is generally viewed positively as a vote of confidence in the company. The 'Beneficial Ownership Blocker' is a structural detail for compliance and not inherently negative.

Positives

• The disclosure of a significant 9.99% stake by Bain Capital Life Sciences, a prominent investment firm specializing in the life sciences sector, can be interpreted as a vote of confidence in Olema Pharmaceuticals' prospects.
• The inclusion of pre-funded warrants in the ownership structure suggests a strategic, long-term investment approach by Bain Capital.

Risks

• The 'Beneficial Ownership Blocker' limits Bain Capital Life Sciences' ability to increase its stake beyond 9.99% through the exercise of pre-funded warrants, potentially capping its direct ownership influence via this mechanism.

Future Outlook

The document is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer or the reporting person regarding future performance, strategic direction, or operational outlook beyond the disclosed ownership stake.

Management Comments

• Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Olema Pharmaceuticals, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing highlights a significant passive investment by a major life sciences-focused private equity firm in a pharmaceutical company. Such investments are a common strategy in the biotechnology and pharmaceutical sectors, where specialized funds aim to capitalize on the long-term growth potential associated with drug development and commercialization. Bain Capital's substantial stake suggests a strategic belief in Olema Pharmaceuticals' underlying value, pipeline, or market position within the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Bain Capital could be perceived positively, potentially boosting investor confidence and market perception of Olema Pharmaceuticals.
• Company Management: The passive nature of the investment, as certified by Bain Capital, suggests no immediate intent to influence management or control, allowing current management to continue their strategic direction without direct pressure from this specific investor.

Next Steps

• The document does not specify any future actions, events, or milestones for Olema Pharmaceuticals or the Reporting Person beyond the disclosure of current ownership.

Key Dates

Keywords

Olema Pharmaceuticals, Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrants, Biotechnology, Pharmaceuticals, Investment, SEC Filing